Scientific knowledge exchange
ESMO 2019: New insights in melanoma treatment
Prof. Reinhard Dummer, MD, University Hospital Zurich, and Prof. Olivier Michielin, MD, PhD, CHUV Lausanne, discuss the current advances and challenges in melanoma treatment with a focus on immunotherapy.
This year’s highlights were new neoadjuvant options, refinement of adjuvant therapy, and a smarter use of immunotherapy to achieve cost-efficiency and prevent side-effects.
Abstracts discussed in the interview:
- Dummer R et al. Primary 2-year (yr) results of a phase II, multicenter, randomized, openlabel trial of efficacy and safety for talimogene laherparepvec (T-VEC) neoadjuvant (neo) treatment (tx) plus surgery (surg) vs surg in patients (pts) with resectable stage IIIB-IVM1a melanoma. #LBA66
- Schadendorf D et al. Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). #LBA67
- Weber J et al. Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial. #1310O
- Lee R et al. ESMO Clinical Practice Guidelines 2: Localised melanoma resected: Adjuvant therapy followed by systemic relapse
- Long G et al. Long-term outcomes from the randomized phase II study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets): Anti-PD1 brain collaboration (ABC). #1311O
- Arance A et al. Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial. #LBA69
ESMO Congress 2019
More from this topic:
ESMO 2019: «Das Darm-Mikrobiom hat viel mit dem Ansprechen auf die Immuntherapie zu tun»
30. 09. 2019